NCT07459634Phase 2Recruiting

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Study sponsor: Jazz Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-08-04Estimated
Enrollment · participants50Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 31 Jan 2028. After: 4 Aug 2029.

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source